Moreno-Uribe N, Martínez-Portilla RJ, Guzmán-Grenfell A

Language: Spanish
References: 25
Page: 374-379
PDF size: 315.73 Kb.

ABSTRACT

Background: Oxidative stress is an altered balance between antioxidant and oxidant systems, leading to cellular damage. In pregnant women with chronic hypertension, oxidative stress has been associated as an important phenomenon for the development of preeclampsia.
Objetive: To determine the usefulness of oxidized albumin and sulfhydryles as an oxidative stress marker in pregnant patients with and without chronic hypertension.
Methods: Cohort study, which included pregnant women from 28 to 30 weeks of gestation, with and without chronic hypertension. Demographic variables serum levels of albumin; oxidized albumin; oxidized albumin/serum albumin index and sulfhydryl were measured by direct spectrophotometry. The final outcome was preeclampsia, diagnosed according to 2013 ACOG Task force. Mean and standard deviation were determined for numerical variables and proportions for qualitative variables. Contingency tables and association measures were performed using c2 for qualitative variables and Mann-Whitney U test for quantitative variables. p ‹0.005 was considered significant.
Results: A total of 24 pregnant women were included, 10 with chronic hypertension and 14 controls. In the chronic hypertension group 3/10 patients developed preeclampsia. No significant differences were found between serum levels of oxidized albumin, oxidized albumin-serum albumin index, and total sulfhydryl levels in the chronic hypertension group in relation to the control group.
Conclusions: In this study, no significant differences were found in oxidative stress molecules serum levels in women with and without chronic hypertension. This may be due to the small number of cases, which requires studies with larger population to rule out this hypothesis.

REFERENCES

1. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/ eclampsia. Semin Perinatol, 2012;36(1):56-9.

2. Khan KS, et al. WHO analysis of causes of maternal death: a systematic review. Lancet, 2006;367(9516):1066-74.

3. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol, 2013;25(2):124-32.

4. van Oostwaard MF, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol, 2015;212(5):624 e1-17.

5. American College of, Gynecologists and P. Task Force on Hypertension in, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol, 2013;122(5):1122-31.

6. Griendling, K.K. and G.A. FitzGerald, Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation, 2003;108(17):2034-40.

7. Griendling, K.K. and G.A. FitzGerald, Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 2003;108(16):1912-6.

8. Kultz, D., Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol, 2005;67:225-57.

9. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta, 2014;35 Suppl S20-5.

10. Myatt L. Review: Reactive oxygen and nitrogen species and functional adaptation of the placenta. Placenta, 2010;31:S66-9.

11. Sanchez-Aranguren LC, et al. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol, 2014;5:372.

12. Rodrigo R, et al. Relationship between oxidative stress and essential hypertension. Hypertens Res, 2007;30(12):1159-67.

13. Hirata, YSH. Hypertension and Oxidative Stress. JMAJ, 2001;44(12):545-2001.

14. Higashi Y, et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med, 2002;346(25):1954-62.

15. Higashi Y, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J, 2009;73(3):411-8.

16. Pan SM, et al. Ischemia-modified albumin measured with ultra-filtration assay in early diagnosis of acute coronary syndrome. World J Emerg Med, 2010;1(1):37-40.

17. Gafsou B, et al. Maternal serum ischemia-modified albumin: a biomarker to distinguish between normal pregnancy and preeclampsia? Hypertens Pregnancy, 2010;29(1):101-11.

18. Prefumo F, et al. First trimester maternal serum ischaemiamodified albumin: a marker of hypoxia-ischaemia-driven early trophoblast development. Hum Reprod, 2007;22(7): 2029-32.

19. Altaany Z, et al. Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide. Curr Med Chem, 2014;21(32):3646-61.

20. Ustun Y, et al. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. J Matern Fetal Neonatal Med, 2011;24(3):418-21.

21. Abril-Díaz NB, Fernández-Reyes JA, Galván-Cejudo A, y col. Espectrofotometría: espectros de absorción y cuantificación colorimétrica de biomoléculas. Prácticas generales de bioquímica y biología molecular 2005. [cited Jan 10, 2017.; Available from: http://www.uco.es/dptos/bioquimica-biolmol/ pdfs/08_ESPECTROFOTOMETR%C3%8DA.pdf.

22. Gomez Paliza J. Laboratory studies and spectrophotometry. Amniotic fluid. Ginecol Obstet Mex, 1966;2122):307-22.

23. Beckman Coulter I. DU 800 Spectrophotometer Installation and Operating Instructions. 2009 Nov, 2009 Jan 10, 2017]; Available from: http://sydney.edu.au/medicine/bosch/facilities/ molecular-biology/DU800 installation and operation Instructions_512860.pdf.

24. Bhakthavatsala Reddy CC, Desle HB. Role of Ischemia Modified Albumin (IMA) in acute coronary syndromes. Indian Heart J, 2014;66(6):656-62.

25. Lunghi L, et al. Control of human trophoblast function. Reprod Biol Endocrinol, 2007;5:6.